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Tamoxifen, an antineoplastic agent, is active in vitro and in vivo against the parasitic protozoa Leishmania.
As part of our efforts to unravel this drug's mechanisms of action against the parasite and understand
how resistance could arise, we tried to select tamoxifen-resistant Leishmania amazonensis. Three
different strategies to generate tamoxifen resistant mutants were used: stepwise increase in drug con-
centration applied to promastigote cultures, chemical mutagenesis followed by drug selection and
treatment of infected mice followed by selection of amastigotes. For amastigote selection, we employed a
method with direct plating of parasites recovered from lesions into semi-solid media. Tamoxifen resis-
tant parasites were not rescued by any of these methods. Miltefosine was used as a control in selection
experiments and both stepwise selection and chemical mutagenesis allowed successful isolation of
miltefosine resistant mutants. These ﬁndings are consistent with a multi-target mode of action to explain
tamoxifen's leishmanicidal properties. Considering that drug resistance is a major concern in anti-
parasitic chemotherapy, these ﬁndings support the proposition of using tamoxifen as a partner in
drug combination schemes for the treatment of leishmaniasis.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Leishmaniasis is a complex of vector-borne infectious diseases
transmitted by sand ﬂies and caused by protozoan parasites of the
genus Leishmania. The disease is widespread in the world in trop-
ical and subtropical regions (Alvar et al., 2012). Recent data indicate
that approximately 0.2e0.4 million and 0.7 to 1.2 million cases of
visceral and cutaneous leishmaniasis respectively occur each year
(Alvar et al., 2012).
The limited drug arsenal available for the treatment of leish-
maniasis presents numerous shortcomings, such as toxicity, the
need for prolonged and mostly parenteral medication and price.
Furthermore, failure has been reported for most drugs used in theN-nitroso-N0-nitroguanidine;
d solution; NBD-PC, 2-(6-(7-
xadecanoyl-sn-glycero-3-
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ol of Medicine, University of
Ltd on behalf of Australian Society ftreatment of the disease (Bryceson, 2001; Croft, 2001) and, in some
settings, this failure has been attributed to drug resistance. Wide-
spread resistance to antimonials is found in the Northeast of India
(Sundar, 2001; Sundar et al., 2001) and there is great concern on the
selection of parasites resistant to miltefosine (Cojean et al., 2012;
Rijal et al., 2013), the ﬁrst oral drug used in the treatment of
leishmaniasis. For all these reasons, there is an urgent need to
discover and develop new antileishmanial drugs as well as strate-
gies to protect current and future therapies from the threat of
resistance.
Drug resistance is related to the ability of pathogens to
circumvent the effects of drugs and is due to the genetic adapt-
ability that enables the selection of appropriate strategies against
these drugs (Vanaerschot et al., 2013). Selection of drug resistant
parasites has been used for the identiﬁcation of drug resistance
genes in parasitic protozoa and has also contributed to under-
standing the mechanisms of action of some of these therapeutic
agents (Ouellette et al., 2004; Muller and Hemphill, 2011; Alsford
et al., 2013). In Leishmania, this strategy has been applied in vitro
using stepwise increase in the concentration of the drug of interest,
followed by the use of different molecular techniques for the
analysis of differentially expressed genes/proteins and for identi-
ﬁcation of point mutations in drug resistant parasites compared to
wild-type lines (Berg et al., 2013; Vanaerschot et al., 2013). Theor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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identiﬁed in a methotrexate selected resistant line of Leishmania
major using this strategy (Beverley et al., 1984, 1986). Stepwise
increase in drug concentration has also been applied to the selec-
tion of miltefosine resistant mutants and this phenotype has been
linked to point mutations on a P-type ATPase, known as miltefosine
transporter (MT), responsible for the translocation of phospholipids
across the plasma membrane (Perez-Victoria et al., 2003; Coelho
et al., 2012, 2014).
We have previously reported that tamoxifen, a selective oes-
trogen receptor modulator, is active in vitro and in vivo against
Leishmania species (Miguel et al., 2007, 2008, 2009). We have
demonstrated that tamoxifen's antileishmanial activity is not
dependent on the interaction with oestrogen receptors (Bonano
et al., 2014) but the precise antileishmanial mechanism of action
is still uncertain. The aim of this work was to apply drug selection
experimental protocols to Leishmania amazonensis with the
objective of developing parasite lines that would be suitable to the
characterization of tamoxifen's mechanism of action.
2. Material and methods
2.1. Drugs
Tamoxifen, tamoxifen citrate, miltefosine and N-methyl-N-
nitroso-N0-nitroguanidine (MNNG) were purchased from Sigma-
eAldrich (St. Louis, MO, USA). Stock solutions of tamoxifen and
miltefosine (10 mM) were prepared in ethanol or sterile water,
respectively. MNNG was diluted in DMSO at a concentration of
10 mg/mL. Tamoxifen citrate was used for the treatment of BALB/c
mice infected with L. amazonensis, prepared daily with saline.
2.2. Parasites and cells
L. amazonensis (MHOM/BR/1973/M2269) promastigotes were
grown in medium 199 (SigmaeAldrich) supplemented with 10%
heat-inactivated fetal calf serum, 0.25% hemin, 12 mM NaHCO3,
50 U/mL penicillin and 50 mg/mL streptomycin at 25 C. Amasti-
gotes were obtained from infected mice, as described (Arruda et al.,
2008). In brief, female BALB/c mice (4e5 week-old) were infected
with 106 stationary-phase parasites injected subcutaneously in the
right hind footpad. After 8e12 weeks, lesions were removed and
homogenized in phosphate-buffered saline (PBS); the suspension
was cleared of cell debris by centrifugation at 50 g for 8 min. The
supernatant containing amastigotes was recovered and washed
three times in PBS. Amastigotes were counted in a Neubauer
hemocytometer.
MCF-7 breast cancer cell line was cultured in DMEM supple-
mented with L-glutamine, glucose and 10% fetal bovine serum (Life
Technologies). This line was maintained in exponential growth
phase by sub-culturing twice weekly in 25-cm2 ﬂasks at 37 C and
5% CO2. For sub-culturing, media was removed from the ﬂasks, cells
were washed with PBS and then detached by incubation with 2 mL
of Trypsin/EDTA solution (Vitrocell Embriolife, Campinas, Brazil) for
5e10 min followed by inactivation with DMEM. Cells were counted
and resuspended in growth media at 105 cells/mL.
2.3. Drug selection in promastigotes
Selection of resistant parasites was initiated using different
concentrations of tamoxifen (2, 4, 6, 8 and 12 mM) and 10 mM of
miltefosine. For miltefosine, the drug was increased using a step-
wise selection until they were resistant to 150 mM. Selection was
performed with at least three successive passages for each dose
(Coelho et al., 2014). For tamoxifen, parasites were kept for at least40 passages in the presence of 12 mM tamoxifen (around 250 days
of treatment) after previous treatment with 8 mM of tamoxifen for
10 passages.2.4. Mutagenesis in vitro
Mutagenesis was applied to L. amazonensis wild-type promas-
tigotes (5  106 parasites/mL in M199 medium) that were initially
treated with 3 mg/mL of MNNG (SigmaeAldrich) for a period of 4 or
24 h at 25 C in a total of at least 250 mL of liquid medium, as
described (Iovannisci and Ullman, 1984). Mutagenized parasites
were then washed three times with PBS and resuspended in fresh
medium at a concentration of 5  106 parasites/mL. Viability post-
treatment was evaluated by cell counting and once the cell cultures
started to grow, mutagenized parasites were submitted to selection
in the presence of 20 mM tamoxifen or 70e75 mM miltefosine. Se-
lection was performed in liquid or semi-solid 199 medium. Para-
sites were seeded in 150 mL of M199 at a density of 2  106
parasites/mL or plated in semi-solid medium at concentration of
4  107 parasites/plate in a total of at least 20 plates.2.5. Drug selection in amastigotes
Mice were infected as described above. Five weeks after infec-
tion, treatment with tamoxifen was initiated. Infected animals
received intraperitoneal injections of 30.4 mg tamoxifen citrate/kg/
day (equivalent to 20 mg/kg/day tamoxifen) for 15 days. Sixty days
after the end of treatment, mice were euthanized and amastigotes
were puriﬁed from lesions. Amastigotes recovered from infected
mice treated or not with tamoxifen were counted and then plated
in medium 199 containing 1% of agar (Invitrogen Corporation, NY,
USA) and 0.6 mg/mL of biopterin (SigmaeAldrich). A total of 5  106
amastigotes were directly plated in triplicate, in plates containing
20, 30 or 50 mM of tamoxifen or in the absence of drug.2.6. Parasite viability
Susceptibility to tamoxifen, miltefosine or MNNGwas evaluated
by a [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide] (MTT, SigmaeAldrich) viability test assay as previously
described (Zauli-Nascimento et al., 2010). Brieﬂy, promastigotes
(2  106 per well) in M199 were incubated in the presence of
increasing concentrations of drug (tamoxifen, 2e128 mM; miltefo-
sine, 3e200 mM or MNNG, 1.5e96 mg/mL assayed at a 2-fold dilu-
tion) for 24 h. MTT cleavage was measured in a microplate reader
(POLARstar Omega, BMG Labtech, Ortenberg, Germany) with a test
wavelength of 595 nm and a reference wavelength of 690 nm.
Assayswere performed in triplicate and results are expressed as the
mean and standard deviation (SD) of at least three independent
experiments.2.7. Uptake of ﬂuorescent phosphocholine
Log-phase promastigotes were labelled with NBD-PC (Molecular
Probes) as described (Coelho et al., 2014). Brieﬂy, parasites were
labelled with 10 mM NBD-PC for 30 min. After washing, parasites
were resuspended in PBS for ﬂow cytometry analysis. Labelled
parasites were analysed at room temperature using Guava EasyCyte
Mini Flow Cytometer System (Millipore). Data from 5000 cells,
deﬁned by gating at data acquisition, was collected and analysed
using CytoSoft version 4.2.1 software (Guava Technologies) and
FlowJo version 9.4.9 software (Tree Star, Ashland, Oregon).
Table 1
Tamoxifen (TM) susceptibility in wild-type and selected lines.
Parasite linesa EC50 ± S.D. (mM)b Fold resistancec
L. amazonensis 2269
(wild-type)
12.66 ± 1.75 1
TM2 13.4 ± 3 1.06
TM4 13.2 ± 1.6 1.04
TM6 11.1 ± 0.1 0.88
TM8.1 9.99 ± 1.64 0.8
TM8.2 11.36 ± 2.07 0.9
TM12.1 13.71 ± 2.86 1.08
TM12.2 12.42 ± 2.34 0.98
a L. amazonensis promastigotes of the wild-type strain and lines selected in the
presence of 2, 4, 6, 8 or 12 mM tamoxifen.
b EC50 ± standard deviation (in mM). Results are the average of at least three in-
dependent experiments.
c Fold resistance is the ratio between the EC50 of selected lines over the EC50 for
the wild-type strain.
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For nucleotide sequencing of the MT gene, total genomic DNA of
L. amazonensis parasites was puriﬁed using DNAzol (Invitrogen). The
MT gene of the miltefosine resistant clones was ampliﬁed by PCR in
two overlapping fragments of approximately 2.8 and 1.3 kbusing two
pairs of primers (Fand R3, 50-CGCTCTAGACACCACCACCACTCCTGCCT-
30 and 50- CGGCATGTGCACCTTCCAGC e 30, and F3 and R, 50-
GCGCAACGACTTCATCGACC e 30 and 50- CGCAAGCTTTCTGCT-
CACGTTCCGCCCTC, respectively). After electrophoresis, PCR ampli-
ﬁed products were puriﬁed from 0.8% agarose gels using QIAquick
PCR puriﬁcation kit (Qiagen, Valencia, USA) and cloned in pGEM-T
easy (Promega Corporation, Madison, WI, USA). All nucleotide se-
quenceswere determined automaticallywith the Big Dye Terminator
v3.1 Cycle Sequencing kit (Life Technologies) using pUC/M13 primers
and internal primers of MT gene of L. amazonensis previously
described (Coelho et al., 2014). Nucleotide sequence analyses were
performed using Lasergene Software (DNASTAR) and CloneManager
9.0 Software.
2.9. Selection of tamoxifen resistant human breast cancer cell lines
and cytotoxicity studies
MCF-7 tamoxifen resistant line was selected by exposing cell
culture to 1 mM tamoxifen during 30 days as described (Coser et al.,
2009; Mo et al., 2013). For cytotoxicity studies, 105 cells/well were
seeded on a 24-well plate. Cells were allowed to attach and grow
overnight and then treated with 1e50 mM tamoxifen. Cells were
incubated for 3 days at 37 C with 5% CO2 followed by detaching
with Trypsin/EDTA solution and cell counting using a Neubauer
hemocytometer. The resistant and sensitive lines were tested in
duplicate for each tamoxifen concentration in three independent
experiments. The EC50s were determined as described above.
2.10. Statistical analysis
The half-maximal effective concentrations (EC50) were deter-
mined from sigmoidal regression of the concentrationeresponse
curves. Growth curves were analysed after calculating the area
under the curve (AUC) for the means of three independent exper-
iments performed with duplicates and compared through one-way
ANOVA followed by Tukey's post-tests. Unpaired two-tailed Stu-
dent's t tests were used to compare EC50 determined inMCF-7 cells.
Statistical analysis were performed using GraphPad Prism 5.0
software (GraphPad Software, Inc., La Jolla, CA USA).
2.11. Ethics statement
Animal experiments were approved by the Ethics Committee for
Animal Experimentation (Protocol: 178/138/02) in agreement with
the guidelines of the Sociedade Brasileira de Cie^ncia de Animais de
Laboratorio (SBCAL) and of the Conselho Nacional de Controle da
Experimentaç~ao Animal (CONCEA).
3. Results
The ﬁrst strategy used with the purpose of selecting tamoxifen-
resistant Leishmania was to submit promastigote cultures to sub-
EC50 concentrations of drug. Since the EC50 against L. amazonensis
promastigotes is 12.66 ± 1.75 mM (Table 1), parasites were culti-
vated in the presence of 2, 4, 6 and 8 mM tamoxifen as the initial
selection condition. While no change in growth was observed at 2
and 4 mM of tamoxifen compared to untreated parasites, a delay in
reaching the exponential phase was observed when parasites were
exposed to 6 and 8 mM of the drug (data not shown). After 5passages, tamoxifen's EC50 was determined for these lines and no
differences were observed in comparison with the EC50 prior to
selection (Table 1). Two independent lines initially selected at 8 mM
(TM8.1 and TM8.2) were kept for 10 passages in the presence of this
drug concentration. At the end of this period, there was no signif-
icant change in tamoxifen's EC50 (Table 1).
Drug concentration on TM8.1 and TM8.2 cultures was then
raised to 12 mM for 40 passages (TM12.1 and TM12.2). Wild-type
parasites were unable to grow in the presence of 12 mM tamox-
ifen (Fig.1). TM12.1 and TM12.2 promastigotes survived at this drug
concentration but their growth curves showed signiﬁcantly
delayed exponential phases and lower densities at the stationary
phase as compared with control wild-type curves (Fig. 1). This
delayed growth pattern was reversible upon removal of the drug
and, in the absence of tamoxifen, the growth curves for TM12.1 and
TM12.2 promastigotes were not signiﬁcantly different from the
control wild-type cells (Fig. 1).
In spite of TM12.1 and TM12.2 ability to survive in the presence
of 12 mM tamoxifen, there was no change in tamoxifen's EC50 after
24 h treatment as compared to the EC50 against parasites not
exposed to the drug (Table 1). Several attempts were made to in-
crease drug pressure in TM12.1 and TM12.2 cultures. However, we
were never able to recover living parasites when tamoxifen con-
centrations were raised to 20 mM or higher.
As a positive control for the drug selection protocol, miltefosine
was used in increasing concentrations against L. amazonensis pro-
mastigotes. Stepwise selection with miltefosine generated highly
resistant mutants with 8-fold increase in the EC50 as compared
with wild-type parasites, after about 100 days in culture (data not
shown and (Coelho et al., 2014)).
Having shown that we could select for drug resistant Leish-
mania, it remained to ascertain whether we could select for
tamoxifen resistance. That was tested using a human breast cancer
cell line, MCF-7, for which it had been previously shown that
exposure to tamoxifen led to selection of resistant lines (Coser et al.,
2009; Mo et al., 2013). MCF-7 cells were cultivated with 1 mM
tamoxifen for 30 days and then evaluated for their susceptibility to
tamoxifen. Tamoxifen's EC50 against the parental MCF-7 cells was
determined as 14.7 ± 3.6 mM (Fig. S1). MCF-7 cells exposed to
tamoxifen for 30 days had their susceptibility signiﬁcantly
decreased with and EC50 calculated as 34.1 ± 4.9 mM (Fig. S1).
Therefore, the lack of resistance to tamoxifen in Leishmaniawas not
due to any faults in the protocol.
An alternative to increasing the frequency of drug resistant
parasites is the use of mutagenic agents. This strategy has already
been applied successfully in the selection of drug resistant parasitic
protozoa, as Toxoplasma gondii and Leishmania (Iovannisci and
Fig. 1. Growth curves for TM12.1 and TM12.2 lines and wild-type L. amazonensis promastigotes in the presence or absence of tamoxifen. Promastigotes were cultivated in M199
medium at 25 C in the absence (TM-) or presence of 12 mM tamoxifen (TMþ). Cultures were seeded at 2  105 cells/mL and parasites were counted using a Neubauer hemo-
cytometer. Data is the mean and standard error from three independent experiments. The AUC was signiﬁcantly different between WT (TM-) and TM12.1(TMþ) or TM12.2 (TMþ)
(ANOVA with Tukey's post-test, P < 0.0001).
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Victoria et al., 2003). MNNG was chosen to generate mutagenized
promastigotes. The toxicity of MNNG against L. amazonensis pro-
mastigotes was evaluated through viability tests allowing the
determination of an EC50 of 3.3 mg/mL ± 0.55 (Fig. 2A). Based on
these ﬁndings, a concentration of 3 mg/mL MNNG was used to treat
parasites for 4 or 24 h followed by a drug-free medium replacement
for growth recovery. Parasites treated with MNNG for 24 h took 8
days to start growing again (Fig. 2B), while parasites treated for 4 h
recovered after 3 days (Fig. 2C). When culture growth was restored,
parasites were selected in the presence of tamoxifen or miltefosine,
in liquid culture and in plates. We were unable to recover living
parasites when 20 mMof tamoxifenwas added to the culturemedia.
On the other hand, MNNG treatment followed by miltefosine se-
lection allowed the recovery of several colonies. For cells treated
with MNNG for 24 h followed by selection at 70 mMmiltefosine, we
observed a 108 recovery efﬁciency while for cells treated with
MNNG for 4 h the efﬁciency was 3.75  107.
Ten resistant clones selected in semisolid medium containing
miltefosine from populations treated for 4 h with MNNG were
transferred to liquid medium containing 80 mM miltefosine. Sus-
ceptibility tests showed that these clones were highly resistant to
the drug with up to 8-fold increases in the EC50 as compared with
the control parasites (Table 2). These resistant lines were also
compared toMF150.3e1, a previously selectedmiltefosine resistant
L. amazonensis line (Coelho et al., 2014) which was found to be
defective in the accumulation of NBD-phosphocholine (NBD-PC)
due to mutations in the MT gene (Coelho et al., 2014). In all ten
clones selected for miltefosine resistance, we observed reduced
accumulation of phosphocholine (Table 2 and Fig. 3). Nucleotide
sequence analysis of theMT alleles in one of these clones (clone 10)
identiﬁed the following mutations: G410E, L512H, T932A, E951K,
T955T and W1005STOP, conﬁrming previous observations corre-
lating resistance to miltefosine in Leishmania to mutations in the
MT gene (Perez-Victoria et al., 2003; Coelho et al., 2012, 2014).
We then made use of in vivo selection to try to identify tamox-
ifen resistant parasites. We had previously shown that mice treated
with tamoxifen exhibited a marked decrease in the size of lesions
and parasite burden but there was no sterile cure (Miguel et al.,
2008). We investigated whether parasites remaining at the lesion
site after tamoxifen treatment displayed altered susceptibility to
the drug. For this evaluation, amastigotes recovered from lesions
were directly plated in M199-agar containing 0, 20, 30 or 50 mM
tamoxifen and incubated at 25 C. Parasites from treated anduntreated animals differentiated and grew as promastigotes
forming colonies in the absence of tamoxifen. However, no growth
was observed when parasites were plated in the presence of drug
(data not shown). Taken together, these data indicate that treat-
ment with tamoxifen does not induce detectable selection of
resistant parasites in vivo.
4. Discussion
Tamoxifen is a nonsteroidal anti-oestrogen compound capable
of binding the oestrogen receptor (Jordan, 1992, 2002). The drug
has a low cost and is widely used in the treatment of oestrogen
receptor positive breast cancer and as a preventive therapy in
women with a high risk of developing the disease (Clarke et al.,
2003). However, tamoxifen resistance in tumour cells does exist
and may be categorized into intrinsic or acquired. Several factors
have been associated with breast cancer resistance to tamoxifen
including silencing of the gene encoding oestrogen receptor a,
mutations in the oestrogen receptor, altered expression of various
growth factor receptors or signalling molecules (reviewed in
(Clarke et al., 2003; Riggins et al., 2007; Musgrove and Sutherland,
2009)). The lack or disturbance of the oestrogen receptor activation
or transduction ultimately leads to the generation of survival sig-
nals that counteract apoptotic death programs. In all instances,
clinical or laboratorial resistance to tamoxifen in tumour cells
seems to be related directly or indirectly to receptor activation.
Previous analyses in our laboratory did not identify an oestrogen
receptor encoding homologue in the genome of Leishmania.
Furthermore, structureeactivity relationship studies have clearly
shown that the antileishmanial activity of SERM-like molecules
was present even when groups required for oestrogen receptor
binding were absent (Bonano et al., 2014). In addition, oestrogen
did not compete out the antileishmanial activity of tamoxifen
(Miguel et al., 2007). All these data indicated that the drug activity
against the parasite is unrelated to the receptor or to activation of
oestrogen receptor-signalling pathways.
In this study, we applied various tools aimed at selecting
tamoxifen resistant L. amazonensis mutants in an attempt to un-
derstand resistance mechanisms and the anti-parasite mode of
action. The protocol employing stepwise increase in drug concen-
tration has been used successfully in the selection of several lines of
drug-resistant Leishmania. For instance, the method was used to
select for resistance against methotrexate (Coderre et al., 1983),
antimony (Callahan and Beverley,1991; doMonte-Neto et al., 2011),
Fig. 2. Activity of MNNG against L. amazonensis. (A) Promastigotes were cultivated in
M199 medium at 25 C for 24 h with increasing concentrations of MNNG and viability
was determined byMTT. (B and C) L. amazonensis promatigotes were treated with 3 mg/
mL of MNNG for 24 h (B) or 4 h (C), washed three times with PBS and seeded at 5  106
cells/mL. Cell density was evaluated daily by counting using a Neubauer hemocy-
tometer. (*) Wild-type parasites were sub-cultured when a density of 2.7  107 cells/
mL was reached.
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miltefosine (Perez-Victoria et al., 2003; Coelho et al., 2012, 2014).
Nevertheless, we were unsuccessful in selecting tamoxifenresistant mutants, even after long and continuous drug treatment
(around 250 days) with concentrations equivalent to the EC50 in
lines TM12.1 and TM12.2 (Table 1). These lines showed an increased
tolerance to the drug (Fig. 1 and Table 1), but did not exhibit
decreased susceptibility.
Three independent investigators, in a timeframe spanning two
years, used this in vitro selection protocol with small variations,
always with the same results. In parallel, miltefosine resistant
parasites as well as MCF-7 cells resistant to tamoxifen were
selected.
Mutagenesis was also employed as a tool to increase the fre-
quency of mutations that could lead to tamoxifen resistance. The
use of MNNG to generate Leishmania resistant to tubercidin and
tunicamycin had been previously described (Iovannisci et al.,
1984; Iovannisci and Ullman, 1984; Kink and Chang, 1987). In
our hands, the mutagenic agent did increase the recovery of
miltefosine resistant mutants but not of tamoxifen resistant par-
asites. On the other hand, these data helped conﬁrm that milte-
fosine resistance can be easily acquired. Furthermore, previous
ﬁndings correlating miltefosine resistance to drastic reductions of
drug accumulation due to speciﬁc point mutations in the MT gene
(Perez-Victoria et al., 2003; Coelho et al., 2012, 2014) were also
conﬁrmed here.
Recently, an alternative method to select for resistance in
Leishmania using macrophage cultures infected with amastigotes
was described (Hendrickx et al., 2014). We employed a different
strategy, using in vivo infections, to verify whether tamoxifen
resistant amastigotes could be selected. After treating
L. amazonensis infected BALB/c mice with tamoxifen, we recovered
the lesion parasites and submitted those to selection by plating in
the presence of tamoxifen. We had previously reported that par-
asites recovered frommice after treatment with tamoxifenwere as
susceptible to the drug as the parasites used to initiate the infec-
tion. However, in those circumstances, parasites differentiated
from amastigotes recovered from the site of infection were grown
as promastigotes without drug pressure for a posterior determi-
nation of tamoxifen's EC50. This method could potentially miss
eventual resistant parasites that, due to a growth disadvantage
would be selected out of the population in the initial rounds of
culture. On the other hand, using the protocol described here,
better conditions were used to allow the identiﬁcation of a
possible mutant. To the best of our knowledge, this is the ﬁrst
description of recovering amastigotes from lesions and selecting
those by plating in semi-solid agar, without any further manipu-
lation. In our hands, the plating efﬁciency was comparable when
seeding the plates with promastigotes or lesion-derived amasti-
gotes. This method also indicated the absence of resistant
parasites.
Taken together, we consider these data to be an indication that
tamoxifen must have multiple targets in the parasite in agreement
with observations in tumour cells where, besides being able to bind
and modulate oestrogen receptor activity, tamoxifen has been
shown to exert other effects such as interference in membranes,
ceramide metabolism, calcium-calmodulin modulation and protein
kinase C activity (Lam, 1984; Custodio et al., 1994; Cabot, 1996; Li
et al., 2012).
Failure to select drug resistant organisms may be considered a
positive trait in drug development. Yet, it is not often described,
partly due to the difﬁculty in knowing how far you have to go to
make sure resistance is unattainable. However, while we cannot
completely dismiss the possibility of ﬁnding tamoxifen resistant
Leishmania, we have gathered enough evidence to rule it out as a
common occurrence and to strengthen the proposition of using
tamoxifen in combinationwith other drugs in the chemotherapy of
the disease.
Table 2
Miltefosine susceptibility in wild-type and miltefosine resistant clones generated after treatment with MNNG.
Parasite lines EC50 ± S.D. (mM)a NBD-PC reduced accumulationb
L. amazonensis 2269 (wild-type) 21.9 ± 0.45 No
MF150.3e1c 167.3 ± 16.8 Yes
MNNG-MF clone 2 108.2 ± 4.27 Yes
MNNG-MF clone 3 120.3 ± 14.4 Yes
MNNG-MF clone 5 121 ± 8.2 Yes
MNNG-MF clone 6 104 ± 9.8 Yes
MNNG-MF clone 8 101.1 ± 12.1 Yes
MNNG-MF clone 10 145 ± 34.1 Yes
MNNG-MF clone 11 117.3 ± 19.1 Yes
MNNG-MF clone 12 76.2 ± 18.21 Yes
MNNG-MF clone 13 128.9 ± 1.8 Yes
MNNG-MF clone 15 110.3 ± 7 Yes
a EC50 ± standard deviation values in mM are indicated. Results are the average of three independent experiments.
b NBD-PC accumulation was determined by FACS as indicated in Fig. 3.
c The miltefosine resistant line MF150.3e1 is an L. amazonensis M2269 strain selected by stepwise selection (Coelho et al., 2014).
Fig. 3. NBD-phosphocholine accumulation in L. amazonensis clones resistant to mil-
tefosine. Wild-type, MF150.3e1 miltefosine resistant line selected in vitro (Coelho
et al., 2014) and miltefosine resistant clones were incubated with the ﬂuorescent
analogue NBD-PC for 30 min at 25 C, washed and evaluated by ﬂow cytometry. Non-
labelled and labelled wild-type parasites are shown in light and dark gray respectively.
MF150.3e1 trace is shown in red and MNNG-MF resistant clones 2, 3, 5, 6, 8, 10, 11, 12,
13 and 15 appear in different shades of blue and green (For interpretation of the ref-
erences to colour in this ﬁgure legend, the reader is referred to the web version of this
article.).
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